Incyte will pay $750 million to add an experimental lymphoma treatment to its research pipeline, announcing a licensing deal with MorphoSys that gives it partial U.S. and exclusive ex-U.S. rights to the German biotech’s drug tafasitimab. Incyte will also invest $150 million in MorphoSys stock and agreed to extend another $1.1 billion in conditional payments should development of tafasitimab hit certain clinical, regulatory and sales milestones. The deal comes on the heels of a significant setback for Incyte’s pipeline. Earlier this month, the biotech disclosed a surprising failure for a drug viewed as important to the company’s future growth prospects. Learn More